Cargando…
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
PURPOSE: Three new therapies have been approved recently for the adjuvant treatment of stage III melanoma, substantially reducing the risk of tumor recurrences. This study evaluates 3 independent data sets to clarify the survival probabilities of patients with stage III melanoma. PATIENTS AND METHOD...
Autores principales: | Garbe, Claus, Keim, Ulrike, Suciu, Stefan, Amaral, Teresa, Eigentler, Thomas K., Gesierich, Anja, Hauschild, Axel, Heinzerling, Lucie, Kiecker, Felix, Schadendorf, Dirk, Stadler, Rudolf, Sunderkötter, Cord, Tüting, Thomas, Utikal, Jochen, Wollina, Uwe, Zouboulis, Christos C., Keilholz, Ulrich, Testori, Alessandro, Martus, Peter, Leiter, Ulrike, Eggermont, Alexander M. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392743/ https://www.ncbi.nlm.nih.gov/pubmed/32530760 http://dx.doi.org/10.1200/JCO.19.03034 |
Ejemplares similares
-
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment
por: Garbe, Claus, et al.
Publicado: (2022) -
Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis
por: Weide, Benjamin, et al.
Publicado: (2013) -
Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma
por: Elsaeßer, Otmar, et al.
Publicado: (2012) -
BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy
por: Meckbach, Diana, et al.
Publicado: (2014) -
Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma
por: Amaral, Teresa, et al.
Publicado: (2020)